HPV: Diagnosis, prevention, and treatment

Clinical Obstetrics and Gynecology

Volumn 55, Issue 3, 2012, Pages 671-680

  Hathaway, Jon K ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

Cervarix; Gardasil; HPV; HPV treatment; HPV vaccine; human papilloma virus

Indexed keywords

IMIQUIMOD; LIQUID NITROGEN; PODOPHYLLIN; PODOPHYLLOTOXIN; WART VIRUS VACCINE;

ANUS CANCER; ARTICLE; COLPOSCOPY; CONDYLOMA ACUMINATUM; CRYOTHERAPY; CURETTAGE; EARLY DIAGNOSIS; ELECTROSURGERY; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INCIDENCE; LASER SURGERY; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PENIS CANCER; PREVALENCE; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VAGINA CANCER; VERRUCA VULGARIS; VULVA CANCER; WART VIRUS;

ANUS NEOPLASMS; COLPOSCOPY; CONDYLOMATA ACUMINATA; CRYOTHERAPY; FEMALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84864399113     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0b013e31825caa36     Document Type: Article

References (48)

1. Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer. 2003;88: 63-73.
2. Howlader N, Noone AM, Krapcho M, SEER Cancer Statistics Review, 1975-2008. 2012; Available at: http://seer.cancer.gov/csr/1975-2008/. Accessed January 26, 2012.
3. Naidu A, Wright JM. The role of the human papillomavirus in oropharyngeal cancer. Tex Dent J. 2011;128:447-454.
4. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oro-pharyngeal cancer. N Engl J Med. 2007;356: 1944-1956. (Pubitemid 46740304)
5. Kreimer AR, Clifford GM, Boyle P, et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14: 467-475. (Pubitemid 40270113)
6. De Vuyst H, Clifford GM, Nascimento MC, et al. Prevalence and type distribution of human papil-lomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer. 2009;124:1626-1636.
7. Koutsky L. Epidemiology of genital human papil-lomavirus infection. Am J Med. 1997;102 (5A):3-8. (Pubitemid 127695953)
8. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNAinwomen with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7:453-459. (Pubitemid 46962343)
9. Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogen-esis. Am J Epidemiol. 2000;151:1158-1171. (Pubitemid 30451948)
10. Goodman MT, Shvetsov YB, McDuffie K, et al. Prevalence, acquisition, and clearance of cervical human papillomavirus infection among women with normal cytology: Hawaii Human Papilloma-virus Cohort Study. Cancer Res. 2008;68: 8813-8824.
11. Pagliusi SR, Teresa Aguado M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine. 2004;23:569-578. (Pubitemid 39473185)
12. Gillison ML, Broutian T, Pickard RK, et al. Prevalence oforal HPV infection in the United States, 2009-2010. JAMA. 2012;307:693-703.
13. Einstein MH, Schiller JT, Viscidi RP, et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis. 2009;9:347-356.
14. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007;297:813-819. (Pubitemid 46333946)
15. Fonseca-Moutinho JA. Smoking and cervical cancer. ISRN Obstet Gynecol. 2011;2011: 847684. DOI: 10.5402/2011/847684.
16. Prokopczyk B, Cox JE, Hoffmann D, et al. Identification of tobacco-specific carcinogen in the cervical mucus of smokers and nonsmokers. J Natl Cancer Inst. 1997;89:868-873. (Pubitemid 27268452)
17. Barton SE, Maddox PH, Jenkins D, et al. Effect of cigarette smoking on cervical epithelial immunity: a mechanism for neoplastic change? Lancet. 1988;2:652-654.
18. Bauer HM, Hildesheim A, Schiffman MH, et al. Determinants of genital human papillomavirus infection in low-risk women in Portland, Oregon. Sex Transm Dis. 1993;20:274-278. (Pubitemid 23286957)
19. Collins S, Rollason TP, Young LS, et al. Cigarette smoking is an independent risk factor for cervical intraepithelial neoplasia in young women: a longitudinal study. Eur J Cancer. 2010;46: 405-411.
20. Sellors JW, Mahony JB, Kaczorowski J, et al. Prevalence and predictors of human papillomavi-rus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. CMAJ. 2000;163:503-508.
21. Vaccarella S, Herrero R, Snijders PJ, et al. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol. 2008;37:536-546. (Pubitemid 351804006)
22. Appleby P, Beral V, Berrington de Gonzalez A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16, 573 women with cervical cancer and 35, 509 women without cervical cancer from 24 epidemio-logical studies. Lancet. 2007;370:1609-1621.
23. Smith JS, Green J, Berrington de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361: 1159-1167. (Pubitemid 36401593)
24. de Villiers EM. Relationship between steroid hormone contraceptives and HPV, cervical intra-epithelial neoplasia and cervical carcinoma. Int J Cancer. 2003;103:705-708.
25. Human Papillomavirus Vaccine. Available at: http://www.fda.gov/ BiologicsBloodVaccines/Vac cines/ApprovedProducts/ucm172678.htm. Accessed January 26, 2012.
26. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931-4939. (Pubitemid 46843434)
27. Rowhani-Rahbar A, Alvarez FB, Bryan JT, et al. Evidence of immune memory 8.5 years following administration of a prophylactic human papillo-mavirus type 16 vaccine. J Clin Virol. 2011;53: 239-243.
28. Schwarz TF, Huang LM, Medina DM, et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health. 2012;50:187-194.
29. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-278. (Pubitemid 40590263)
30. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-1927.
31. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papil-lomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-1943. (Pubitemid 46740303)
32. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intra-epithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89-99.
33. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199:926-935.
34. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009;199:936-944.
35. The FUTURE II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection.J Infect Dis. 2007;196:1438-1446.
36. Olsson SE, Kjaer SK, Sigurdsson K, et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5: 696-704.
37. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373:1949-1957.
38. Boss DS, Schwartz GK, Middleton MR, et al. Safety, tolerability, pharmacokinetics and phar-macodynamics of the oral cyclin-dependent kin-ase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours. Ann Oncol. 2010;21:884-894.
39. Frequently asked questions about HPV Vaccine Safety. Available at: http://www.cdc.gov/vaccine-safety/Vaccines/HPV/hpv-faqs.html. Accessed January 26, 2012.
40. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401-411.
41. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. Morb Mortal Wkly Rep. 2009;58: 997-1001.
42. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem. 2005;51:1845-1853. (Pubitemid 41368175)
43. Mayrand MH, Duarte-Franco E, Coutlee F, et al. Randomized controlled trial of human papillomavi-rus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer. 2006;119:615-623. (Pubitemid 43955716)
44. Sexually transmitted diseases, Treatment Guidelines, 2010. Available at: http://www.cdc.gov/std/treat ment/2010/default.htm. Accessed January 26, 2012.
45. Tyring SK, Arany I, Stanley MA, et al. Arandom-ized, controlled, molecular study of condylomata acuminata clearance during treatment with imi-quimod. J Infect Dis. 1998;178:551-555. (Pubitemid 28347944)
46. Chumworathayi B, Thinkhamrop J, Blumenthal PD, et al. Cryotherapy for HPV clearance in women with biopsy-confirmed cervical low-grade squamous intraepithelial lesions. Int J Gynaecol Obstet. 2010;108:119-122.
47. Aerssens A, Claeys P, Garcia A, et al. Natural history and clearance of HPV after treatment of precancerous cervical lesions. Histopathology. 2008;52:381-386. (Pubitemid 351208067)
48. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin no. 109: cervical cytology screening. Obstet Gynecol. 2009;114: 1409-1420.